Other
Neuralink's devices remain investigational, with regulatory approval and commercial-market access still unresolved; clinical and surgical risks remain material.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Aug 5, 2026
Overview
Neuralink is a privately held biotechnology/neurotechnology company developing implantable brain-computer interfaces (BCIs) intended to translate neural activity into computer, robotic-arm, wheelchair, and eventually speech or vision commands. Its current work is investigational and centered on clinical trials for people with paralysis and ALS.
Primary product
N1 implant and associated Telepathy brain-computer-interface system, including a surgical robot and software that decode neural signals to control digital devices; investigational applications also include speech restoration, vision restoration (Blindsight), and mobility.
Founded
2016
Headquarters
Austin, Texas, United States
Team size
201-500 (public LinkedIn estimate; approximately 427)
Work style
Onsite
Industry
Biotechnology research
Sub-industry
Implantable brain-computer interfaces / neurotechnology / medical devices
Offices
Austin / Del Valle, Texas
South San Francisco, California
Fremont, California
Business model
Venture-funded R&D and clinical development
Future medical-device commercialization
Potential licensing, platform, and clinical-use revenue
Funding
Stage
Late-stage private company; Series E (with an additional 2026 Series E-II reported by CB Insights)
Total raised
$1.3B
Latest round
Series E-II · May 2026
May 2026 · Oman Investment Authority
Jun 2025 · Not publicly identified in Neuralink announcement; Reuters/Semafor reported Founders Fund involvement in the financing
People & investors
Leadership
Jared Birchall
Chief Executive Officer
Co-founder, President & COO
Matthew MacDougall
Head of Surgery / Head Neurosurgeon
Kevin B.
Implant Firmware Team Lead
Grant Yoo
Research Team Leader
John W.F. To
Head of Brain Interfaces Materials
Lesley Chan
Microfabrication R&D Team Lead
Claire Castillo
Director of Technology Research and Development, Brain-Brain Interface
Work & culture
The company describes an interdisciplinary, high-intensity environment emphasizing open communication, collaboration, transparency, first-principles problem solving, best ideas regardless of source, rapid advancement, and outsized individual impact. Public job materials suggest substantial onsite laboratory, manufacturing, surgery, and clinical work.
Work style
Onsite
Visa sponsorship
Yes
Compensation
Public job postings show base salary examples around $150,000-$281,000 for a Software Engineer, BCI Applications role, plus RSUs for full-time employees. Department of Labor-derived aggregators report H-1B filings and sponsored-role base salaries broadly around $80,000-$196,000 depending on role and location; these are signals, not guaranteed offers.
Benefits
Medical, dental, and vision PPO insurance
Paid holidays
Commuter benefits
Meals provided
Restricted stock units for full-time employees
401(k) plan
Parental leave
Flexible time off
Product & market
Pricing
No public commercial pricing; devices remain investigational and are not commercially available or FDA approved.
Differentiators
- —Wireless implantable BCI with high channel count
- —Flexible threads designed for minimally invasive robotic implantation
- —Integrated implant, surgical robot, firmware, decoding software, and clinical-trial infrastructure
- —Direct control of computers and physical devices by thought
- —Ambition to expand from motor control to speech, vision, and whole-brain interfaces
- —Rapid iteration using direct clinical-participant feedback
Technology
N1 implant
1,024-electrode neural interface
Flexible electrode threads
Scale & contact
Estimated revenue
Approximately $20M-$30M annually (third-party LinkedIn/company-data estimate; not publicly reported financial revenue)
Signals & risks
Other
Feb 2025Reuters reported that FDA employees involved in reviewing Neuralink and other BCI clinical-trial applications were among broader federal workforce cuts, potentially affecting regulatory-review continuity.
SourceOther
Jul 2026Neuralink reported a new transdural implantation approach in a Canadian clinical trial; the approach is promising but remains early-stage and investigational.
Latest news
Yahoo Tech · Jul 2026
Reported demonstrations in which participants used Neuralink signals to control powered wheelchairs; the system remains investigational.
ALS News Today · Jul 2026
The company reported a first human transdural procedure in Canada's CAN-PRIME trial, intended to simplify surgery and improve scalability.
Inside BCI · Jul 2026
Reported the first Canadian ALS participant and described expansion of Neuralink's international clinical-trial program.
Neuralink · Jun 2025
Neuralink announced a $650M Series E and described five human pioneers, international clinical trials, and progress toward speech, vision, and broader brain-interface applications.
Open Positions
83 jobs at Neuralink
Digital Verification Engineer
On-site
Brain Interfaces Hardware
South San Francisco, California, United States
1d ago
On-site
Full-time